Common use of ChemoCentryx’s Responsibilities Clause in Contracts

ChemoCentryx’s Responsibilities. During the Research Term and each Early Development Program Term, and consistent with the Research Plan and Early Development Plan(s), as updated or amended from time to time, ChemoCentryx shall: (a) have the right and responsibility to manufacture, or have manufactured, the Collaboration Compounds prior to GSK’s exercise of its Product Option with respect thereto, including all required bulk drug substance and clinical materials. ChemoCentryx will keep the JSC advised of its manufacturing plans and activities; (b) conduct all research and development activities it reasonably determines are required to identify and develop Collaboration Compounds, including screening for new antagonists (or agonists as applicable) of Collaboration Targets as necessary and conducting medicinal chemistry with respect to potential leads and lead series, as well as the identification and development of at least two Back-up Compounds to CCX282 against CCR9 which do not have the intellectual property issues associated with CCX282 (as described in Article 6 below) and at least two Back-up Compounds to each other Development Candidate for each other Collaboration Target, in accordance with Section 3.6.2. (c) conduct all Pre-Clinical Activities and Clinical Studies, up to and including all PoC Trials for Development Candidates, as deemed necessary or desirable by ChemoCentryx, in accordance with the applicable Early Development Plan; (d) conduct formulation development of Collaboration Compounds consistent with the Early Development Plans; (e) keep GSK informed through the JSC meetings and of progress being made by ChemoCentryx with respect to the Research Program and any Early Development Program; *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. (f) execute the instructions of the JSC with respect to potential Indications which should or should not be addressed by the appropriate Development Candidates, except as otherwise expressly stated in this Agreement with respect to CCX282 or a CCR9 Back-up Compound; (g) consider in good faith all reasonable suggestions received from GSK regarding the Research Program and any Early Development Program; and (h) perform such other obligations with respect to the Research Program, each Early Development Program, and the PoC Trial plans as the JSC may assign to ChemoCentryx from time to time, and consistent with the Research Plan and Early Development Plans.

ChemoCentryx’s Responsibilities. During the Research Term and each Early Development Program Term, and consistent with the Research Plan and Early Development Plan(s), as updated or amended from time to time, ChemoCentryx shall: (a) have the right and responsibility to manufacture, or have manufactured, the Collaboration Compounds prior to GSK’s exercise of its Product Option with respect thereto, including all required bulk drug substance and clinical materials. ChemoCentryx will keep the JSC advised of its manufacturing plans and activities; (b) conduct all research and development activities it reasonably determines are required to identify and develop Collaboration Compounds, including screening for new antagonists (or agonists as applicable) of Collaboration Targets as necessary and conducting medicinal chemistry with respect to potential leads and lead series, as well as the identification and development of at least two Back-up Compounds to CCX282 against CCR9 which do not have the intellectual property issues associated with CCX282 (as described in Article 6 below) [***] and at least two Back-up Compounds to each other Development Candidate for each other Collaboration Target, in accordance with Section 3.6.2. *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. (c) conduct all Pre-Clinical Activities and Clinical Studies, up to and including all PoC Trials for Development Candidates, as deemed necessary or desirable by ChemoCentryx, in accordance with the applicable Early Development Plan; (d) conduct formulation development of Collaboration Compounds consistent with the Early Development Plans; (e) keep GSK informed through the JSC meetings and of progress being made by ChemoCentryx with respect to the Research Program and any Early Development Program; *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.; (f) execute the instructions of the JSC with respect to potential Indications which should or should not be addressed by the appropriate Development Candidates, except as otherwise expressly stated in this Agreement with respect to CCX282 or a CCR9 Back-up Compound; (g) consider in good faith all reasonable suggestions received from GSK regarding the Research Program and any Early Development Program; and (h) perform such other obligations with respect to the Research Program, each Early Development Program, and the PoC Trial plans as the JSC may assign to ChemoCentryx from time to time, and consistent with the Research Plan and Early Development Plans.